Articles On Neuren Pharmaceuticals (ASX:NEU)

ASX health sector fall in line with broader markets as macroeconomic factors create uncertainty Clinuvel down as its European label expansion of SCENESSE knocked back pending further data 2023 biotech market darling elevated to the S&P...

Harvey Norman booted out of S&P ASX 100 as lithium play Liontown Resources admitted 2023 market darling of ASX biotech sector Neuren Pharmaceuticals a new addition to S&P ASX 200 The scent of blooming flowers, a gentle warming sun...

It’s that time of the year again when S&P Dow Jones Indices announces the rebalance of the S&P/ASX Indices. According to the release, there will be a total of five companies entering the S&P/ASX 200 Index (ASX: XJO) at the n...

ASX health sector rises in line with broader markets as reporting season comes to end EBR Systems on schedule for key US FDA submission in Q1 CY24 for (WiSE) CRT system Health imaging company Mach7 achieves record sales order book of $40.3...

Welcome to the FNArena Corporate Results Monitor. Today's Reports: ((AIS)) - Aeris Resources ((AGI)) - Ainsworth Game Technology ((ALX)) - Atlas Arteria ((ATA)) - Atturra ((AUA)) - Audeara ((ASB)) - Austal ((BUB)) - Bubs Australia ((CCX))...

ASX healthcare stocks haven’t done so well as a collective over the past 12 months. The S&P/ASX 200 Health Care Index (ASX: XHJ) is down 8% over the past year. By comparison, the market benchmark S&P/ASX 200 Index (ASX: XJO) is u...

Neuren’s US FDA approval for trofinetide has seen its share price boosted ~130% in past year   Eye disease specialist Opthea is undertaking two Phase 3 trials to treat Wet AMD with results due in mid 2024 Anteris Technologies is developing...

MoneyTalks is Stockhead’s regular drill down into what stocks investors are looking at right now. We’ll tap our extensive list of experts to hear what’s hot, their top picks, and what they’re looking out for. Today we hear from Peak Asset M...

MoneyTalks is Stockhead’s regular recap of the ASX stocks, sectors and trends that fund managers and analysts are looking at right now. Today we hear from Andrew Chapman, managing director of Merchant Group Australia.   What sector is hot r...

ASX health stocks fall 1.82% in the past five days in line as broader markets rise slightly Resmed sinks after delivering a mixed quarterly result including margins contracting Weight loss drug frenzy drives global big pharma plays Nova No...

ASX health stocks up 1% in the past five days in line with broader markets Volpara records third quarter of positive cashflow following successful growth strategy Gut health a popular theme at 17th Bioshares Biotech Summit along with immun...

ASX 200 climbed to a 100-day high  Energy and Mining retreated after a flurry of earnings reports Fortescue Metals fell despite delivering at the top end of guidance   Local shares jumped by another 0.75% on Wednesday, touching a 100-day...

ASX-listed AusBiotech member Neuren Pharmaceuticals (ASX:NEU) has received the Blake Award for Excellence after a successful year, including an FDA approval and key commercial partnerships.

The ASX 200 built a platform for success today. Which failed. It fell flat at close Sectors wise, Financials, IT and Industrials did okay. The others, very much including Health Care and Utilities, didn’t Notable performers today: Nuix (AS...

These are the stories that are the stuff of dreams for every single ASX All Ords shares investor. Buying at the exact right time… to capture extraordinary share price growth… in a very short period. So hard to do. But we love the stories...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to record a decline. At the time of writing, the benchmark index is down 0.35% to 7,271.9 points. Four ASX shares that are not letting that hold them back are listed be...

Neurotech is following in the footsteps of 2023 market darling of the ASX biotech sector Neuren with another possible treatment for Rett Syndrome. Biopharmaceutical company Neurotech International (ASX:NTI) has hopes of becoming the world’...

Neuren Pharmaceuticals (ASX:NEU) has announced the global expansion of its partnership with US company Acadia Pharmaceuticals for DAYBUE (trofinetide).

The ASX will open flattish as Wall Street finished modestly lower on Friday US banks were mixed following Q2 results The current tech rally is “not the dotcom bubble”, says analyst   Aussie shares are poised to open flattish on Monday fol...

ASX health stocks fall in  past five days with Power noting larger names trading on attractive valuations  Neuren Pharmaceuticals has expanded its current licensing agreement with Acadia Pharmaceuticals Pharmaxis reports positive results f...

Junior biotech Neuren Pharmaceuticals has signed an expanded licensing deal with its US distribution partner Acadia to expand the sale of its drug Daybue to global markets, pushing its stock price up by 16.24% today, trading at $13.53 per...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to end the week on a high. At the time of writing, the benchmark index is up 0.9% to 7,312.5 points. Four ASX shares that are climbing more than most today are listed b...

ASIC plans to establish a stakeholder advisory group to oversee ASX's troubled CHESS replacement project, which ASX supports and sees as a means to enhance transparency and stakeholder engagement in the development of critical clearing and...

Neuren Pharma share price jumps after extending partnership deal with Acadia Acadia will now be the exclusive licence holder for DAYBUE globally Neuren is set to receive hundreds of million of dollars in milestone payments   Market darlin...

Neuren Pharmaceuticals (NEU) receives $145 million from its partner Acadia Pharmaceuticals to expand its North American drug license of trofinetide into global markets The company also stands to make up to $620 million from ongoing miles...

  Neuren Pharmaceuticals (ASX:NEU) announced the expansion of its partnership with Acadia Pharmaceuticals (NASDAQ:ACAD). Neuren is set to receive US$100 million up-front, plus additional potential milestone payments of up to US$427 million,...

Magnis Energy Technologies Ltd (ASX: MNS) shares won’t be going anywhere again on Friday. That’s because this vertically integrated lithium-ion battery technology and materials company’s shares have been in a trading halt since yeste...

The Neuren Pharmaceuticals Ltd (ASX: NEU) share price is on course to end the week on a very positive note. In early trade, the pharmaceuticals company’s shares are up 26% to $14.69. This means its shares are now up 265% over the last 12...

Australian shares are set to open in the green after tech stocks rallied strong trade on Wall Street overnight and the Nasdaq topped the 4500 mark. Treasurer Jim Chalmers will break the news of Australia’s next RBA governor after a cabin...

14 Jul 2023 - A snapshot of the stocks on the move, featuring Neuren Pharmaceuticals (ASX:NEU), Green Technology Metals (ASX:GT1) and One Click Group (ASX:1CG).

ASX health stocks have fallen in the past five days in line with broader markets Mach7 wins a US$60 million Veterans contract – the most significant in its history Neuren completes recruitment for Phase II trial of NNZ-2591 in Phelan-McDer...

ASX All Ords shares closed out FY23 with a solid 8.85% gain but as shown in the chart below, it was a rollercoaster ride that most of us would never want to be on! The S&P/ASX All Ordinaries Index (ASX: XAO) experienced a tumultuous 1...

Neuren Pharmaceuticals (ASX:NEU) has announced that the first site in the US for its Phase 2 clinical trial of NNZ-2591 in Prader-Willi syndrome is now open.

Neuren Pharmaceuticals (NEU) opens the first site in the United States for its phase two clinical trial in Prader-Willi syndrome Neuren’s open-label, phase two trial will be conducted in up to 20 children with the condition to examine th...

Ramsay Healthcare rises after announcing it is looking to sell its joint Asian venture Neuren announces first US site for its Phase 2 clinical trial for Prader-Willi syndrome Microba starts Phase 1 clinical trial for IBD Therapeutic for u...

Avita Medical receives US FDA premarket approval for its RECELL System to treat vitiligo Telix will buy UK medical device firm Lightpoint Medical and its radio-guided surgery business SENSEI Antisense in strong position with new CEO, forme...

Sigma offers very competitive terms to win back Chemist Warehouse contract from Rival EBOS  Pacific Edge slumps ~60% after the US Medicare ended coverage for its Cxbladder test Avita Medical gets US FDA premarket approval for use of its RE...

Australian company Neuren Pharmaceuticals (ASX:NEU) has received the US$40 million milestone payment of US$40 million from Acadia for the US approval and first sale of its treatment for Rett syndrome.

By Tim Boreham ASX code: ((DXB)) Share price: 7.0c Shares on issue: 320,748,666* Market cap: $22.5m Chief executive officer: Dr Nina Webster Board: Hugh Alsop (chair), Dr Webster, Dr Sonia Poli, Clinton Snow Financials (March quarter 2023):...

The final day of the trading week saw the ASX finish in the green up 0.48 per cent. This comes after the US senate voted to suspend the country’s debt ceiling until 2025, avoiding a potentially catastrophic default. In the green U...

Biotech is making a comeback in 2023 There’s been a couple of breakthroughs on the ASX this year We take a look at the ASX biotech winners in May   There are clear signs the biotech sector is springing back to life after a disappointing 2...

A market analyst has outlined why three ASX shares are a buy in the eyes of the team at Bell Potter. The Neuren Pharmaceuticals Ltd (ASX: NEU), Gold Road Resources Ltd (ASX: GOR) and Accent Group Ltd (ASX1) share prices could all have an...

Wall Street was closed for Memorial Day, European shares were slightly down Beware of “downside correction” in the US market, expert says Rampant short-selling is putting pressure on the oil markets   Wall Street was closed for Memorial D...

The market shows that biotechs are making a gradual comeback in 2023 What are some of the catalysts that will push this momentum further? ASX biotechs that announced FDA breakthroughs this year   After a challenging 2022, we are finally s...

EBR announces positive results of its pivotal SOLVE-CRT trial at Heart Rhythm 2023 in US EBR latest ASX biotech company to achieve a key catalyst, opening door to US$2.5 billion market Company now working on regulatory and commercialisatio...

Orphan diseases are those impacting less than 200,000 patients Orphan drug designation ensures an exclusivity period for pharma companies The average orphan drug in the US retails for US$7,000 per month   Rare or ‘Orphan’ diseases affect...

ASX health stocks rise in the past five days in line with broader markets Immutep  surges 46% after positive Phase 2 results into lung cancer Avita Medical falls 28% in past five days despite reporting “solid Q1 FY23” results Healthcare a...

ASX health stocks rise in the past five days outperforming broader markets Avita Medical product sales up 40% on pcp to US$10.5 million in Q1 FY23 Proteomics International Laboratories inks a deal with Sonic Healthcare USA Healthcare and...

Have you ever wondered which ASX shares rich people have bought? Maybe you’d like to emulate their portfolio? Surely if they’re wealthy then they must know what they’re doing? Well, the cat need not be killed because this week investment p...

ASX health stocks fall 0.8% in the past five days in line with broader markets following latest rate hike Investors rewarding health stocks with near term catalysts in 2023, including Neuren and Impedimed Health imaging stock Volpara recor...